New EU breast cancer approvals are reshaping biomarker testing, ADC sequencing and first-line TNBC care. Authors: Katarzyna Pogoda, Barbara Radecka doi.org/10.5603/ocp.114860 #BreastCancer #Oncology #ClinicalPractice

Lower hemoglobin and lower lymphocyte-to-monocyte ratio (LMR) were independently associated with shorter overall survival in patients with metastatic colorectal cancer treated with targeted biological agents. Their predictive value remains uncertain. doi.org/10.5603/ocp.114424

Adult colonic intussusception can signal malignancy. A 20-year-old woman was found to have mucinous ascending-colon adenocarcinoma and FAP. Authors: Julia Ciesielska, Szymon Niemiec, Andrzej Guzik, Joanna Kobak. doi.org/10.5603/ocp.112828 #ColorectalCancer

BRAF/MEK therapy led to complete regression of a right atrial melanoma metastasis, highlighting the potential role of targeted therapy and serial echocardiographic monitoring in cardiac involvement. doi.org/10.5603/ocp.112654 #Melanoma #CardiacMetastasis #BRAFV600E #Oncology

Fatal pulmonary hypertension after 17 months of alectinib in a 39-year-old woman with ALK+ NSCLC. The case suggests a rare ALK-inhibitor vascular toxicity, though causality was not confirmed. doi.org/10.5603/ocp.113041 #NSCLC #Alectinib

Case report: squamous cell lung cancer in a 25-year-old man after short-term asbestos exposure. Authors: Tobiasz Wróblewski, Katarzyna Ostrowska, Paulina Wesołowska, Filip K. Gajewski, Beata Gryglicka, Karolina Dubiel-Kosikowska, Paweł Krawczyk doi.org/10.5603/ocp.113154 #NSCLC

A narrative review explores ICI efficacy in rare oncogene-driven NSCLC. BRAF-mutated tumors appear most responsive, while targeted therapies remain preferred for most subgroups. Authors: Paulina Kalman, Magdalena Knetki-Wróblewska doi.org/10.5603/ocp.113505 #NSCLC #Immunotherapy

A rare case of dynamic HER2 discordance in breast cancer shows how receptor status may change over time and after treatment, highlighting the value of repeat biomarker reassessment in recurrent or residual disease. doi.org/10.5603/ocp.111460 #BreastCancer #HER2 #Oncology

Cancer cachexia requires multimodal care. This review highlights early, individualized management combining nutrition, exercise, pharmacotherapy and emerging targeted therapies. Authors: Zuzanna Kościów, Klaudia Gutowska. doi.org/10.5603/ocp.113525 #Cachexia #Oncology

Poland: #ProstateCancer incidence rose in 2013–2023; age-standardized mortality stayed broadly stable but remains above the EU average. Authors: Michał Seweryn, Paweł M. Potocki, Janusz Ligeza, Anna B. Łuc-Seweryn, Paweł Koczkodaj doi.org/10.5603/ocp.113452 #Oncology

New review of nectins and nectin-like molecules in melanoma, lung cancer and RCC. Nectin-4 and CD155/TIGIT are highlighted as key targets for ADCs, checkpoint blockade and oncolytic virotherapy. journals.viamedica.pl/oncolo… #Nectins #Nectin4 #TIGIT #Melanoma #LungCancer #Oncology

Interim UROCAPOL data suggest split-dose cisplatin may be underused in metastatic urothelial carcinoma. Avelumab ORR was 66.7% after split-dose GC vs 12.5% after GK. journals.viamedica.pl/oncolo… #UrothelialCancer #Avelumab

#Atezolizumab may be a first-line option for older patients with advanced #NSCLC who cannot receive platinum doublets. Full article: journals.viamedica.pl/oncolo…

Can DDR1 help overcome resistance to ICI therapy in CRC? This review highlights its role in the tumor microenvironment and potential as a therapeutic target in pMMR/MSS disease. Authors: Jiali Zhang, Huixiu Liu, Chiyu Zhang, Xiong Bin journals.viamedica.pl/oncolo…

KIF5B-ALK–positive lung adenocarcinoma showed a partial response to crizotinib, underscoring the value of broad molecular profiling for targeted therapy. journals.viamedica.pl/oncolo… #LungCancer #NSCLC #Crizotinib

Antibody–drug conjugates are transforming breast cancer treatment. This systematic review highlights efficacy across subtypes while emphasizing key challenges, including optimal sequencing and toxicity management. journals.viamedica.pl/oncolo… #BreastCancer #Oncology

ECOG performance status is a strong independent prognostic factor for survival in mNSCLC patients treated with nivolumab after platinum-based chemo. journals.viamedica.pl/oncolo… #NSCLC #Nivolumab

When is it not metastasis? In EGFR-mutated NSCLC, an ampulla of Vater lesion proved to be a second primary adenocarcinoma, highlighting clinical, imaging, pathology and molecular integration. journals.viamedica.pl/oncolo… #NSCLC #EGFR

Ipilimumab monotherapy after anti-PD-1 progression shows limited effectiveness in advanced melanoma, though a small subset may benefit. journals.viamedica.pl/oncolo… #Melanoma #Ipilimumab #Immunotherapy #AntiPD1 #AntiCTLA4 #AdvancedMelanoma #Oncology #CancerResearch #ClinicalOncology

let-7c-3p acts as a tumor suppressor in papillary thyroid carcinoma by targeting CXCL3, inhibiting cell growth, migration, and invasion. Authors: Ningjie Duanmu, Rui Yang, Jing Li Full paper: journals.viamedica.pl/oncolo… #ThyroidCancer #miRNA #let7c3p #CXCL3 #CancerResearch